# Androgenetic Alopecia

Diagnose androgenetic alopecia by patterned miniaturization, use trichoscopy to distinguish competing alopecias, and initiate durable pharmacotherapy before irreversible density loss. Treatment selection differs substantially by sex, reproductive potential, distribution, and coexisting shedding or scarring disease.

**Clinical question:** How should clinicians confirm androgenetic alopecia, exclude important mimics, and select evidence-supported long-term treatment?

Updated: 2026-09-15T23:13:56.208851+00:00

## What matters in practice
- Patterned thinning with hair-shaft diameter variability supports androgenetic alopecia, but loss of follicular openings or anagen roots on a positive pull test should redirect evaluation toward scarring alopecia. [14][24]
- Topical minoxidil and oral finasteride 1 mg daily have randomized-trial support in men; minoxidil is the FDA-approved pharmacologic option for female pattern hair loss. [11][22][23]
- Treatment must be continued to preserve benefit; discontinuing minoxidil is followed by shedding of minoxidil-dependent hairs. [8]
- Use scalp biopsy when clinical examination and trichoscopy do not resolve androgenetic alopecia versus an inflammatory or scarring process. [9][14][24]

## Confirm miniaturization and identify diagnoses that change management

The first decision is whether patterned thinning represents isolated androgenetic alopecia or a competing alopecia requiring different treatment.

Diagnose androgenetic alopecia clinically when gradual patterned density loss is accompanied by progressive conversion of terminal hairs to thinner, shorter, and ultimately vellus hairs in involved scalp. In men, androgen-dependent follicular miniaturization and dihydrotestosterone are central therapeutic targets; in women, androgenetic alopecia remains a key cause of chronic patterned thinning but must be distinguished from chronic telogen effluvium, diffuse alopecia areata, and scarring alopecias. [9][22][23]

Perform trichoscopy at frontal/vertex and occipital reference sites when the pattern is subtle, diffuse, or accompanied by active shedding. Hair-shaft diameter diversity supports androgenetic alopecia; yellow dots and thin hairs are also reported features. In female-patterned loss, two major criteria—more yellow dots, more thin hairs, or reduced average frontal hair thickness—or one major plus two minor criteria are diagnostic in the cited trichoscopy study, with 92% specificity. [6][24]

Do not label diffuse shedding as androgenetic alopecia solely from crown predominance. A positive pull test with regular telogen roots can support acute telogen effluvium in the appropriate exposure setting, whereas anagen roots in pulled hairs should raise concern for active scarring disease; in the reported cases, biopsy confirmed lichen planopilaris. Dystrophic hairs can be an early clue to alopecia areata incognita. [14]
- Loss of follicular openings on trichoscopy indicates a scarring process rather than uncomplicated androgenetic alopecia and warrants biopsy-directed evaluation. [24]
- Exclamation-mark hairs favor alopecia areata; comma hairs favor tinea capitis rather than androgenetic alopecia. [24]
- Obtain a scalp biopsy when trichoscopy and examination leave uncertainty about scarring alopecia, diffuse alopecia areata, or mixed disease; horizontal sections quantify terminal-to-vellus change, hair-cycle phase, fibrosis, and inflammation. [9][14][24]

*Trichoscopic and hair-pull findings that redirect the diagnostic pathway. [6][14][24]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Hair-shaft diameter diversity; yellow dots; thin hairs | Supports androgenetic alopecia. [6][24] | Document patterned distribution and begin long-term medical treatment if no competing process is suspected. [11][22][23] |
| Loss of follicular openings | Suggests scarring alopecia. [24] | Perform scalp biopsy to establish the inflammatory/scarring diagnosis. [14][24] |
| Anagen roots on positive pull test | Suggests progressive scarring process in the reported trichoscopy-assisted pull-test cases. [14] | Prioritize biopsy rather than escalating androgenetic alopecia therapy. [14] |
| Dystrophic hairs | May identify alopecia areata incognita among patients with profuse shedding. [14] | Evaluate for diffuse alopecia areata rather than assuming telogen effluvium or androgenetic alopecia. [14] |
| Comma hairs | Pathognomonic marker of tinea capitis. [24] | Treat and investigate as fungal scalp disease, not androgenetic alopecia. [24] |

## Select first-line therapy for men and set expectations for continuous use

Use pharmacotherapy early when the diagnosis is secure and the patient seeks preservation or regrowth.

For men with androgenetic alopecia, topical minoxidil 5%, oral finasteride 1 mg daily, and low-level laser therapy have randomized-trial or meta-analytic evidence for improving hair growth relative to placebo. The finasteride pivotal program enrolled men aged 18 to 41 years and found improvement by hair count, patient and investigator assessment, and expert photographic review at 1 and 2 years with 1 mg daily. [11][22]

Discuss treatment as maintenance therapy rather than a finite course. Continued topical minoxidil use maintains its effect and slows further loss, while stopping minoxidil leads to rapid shedding of minoxidil-dependent hairs. Establish standardized baseline photographs before treatment so follow-up assesses trajectory rather than day-to-day perceived shedding. [8][9]

Choose finasteride when an oral 5-alpha-reductase inhibitor is acceptable after counseling, and choose topical minoxidil when avoiding systemic antiandrogen exposure is prioritized. Combination therapy is a reasonable evidence-informed option because trials and reviews include combined oral finasteride plus topical minoxidil; however, patients should understand that both therapies require durable adherence. [16][22]
- Topical minoxidil: 5% formulation has evidence of benefit in men. [11][19]
- Oral finasteride: 1 mg once daily improved outcomes versus placebo at 1 and 2 years in trials of men aged 18 to 41 years. [22]
- Low-level laser therapy: evidence synthesis supports efficacy in men, but it is an adjunct or alternative when medication preference, tolerance, or access drives selection. [11][16]

*Evidence-supported nonsurgical options for male androgenetic alopecia. [11][16][19][22]*

| Option | Evidence-supported regimen or modality | Best use and treatment constraint |
| --- | --- | --- |
| Topical minoxidil | 5% topical minoxidil. [11][19] | Use for pharmacologic monotherapy or with finasteride; ongoing use is necessary to maintain minoxidil-dependent hairs. [8] |
| Oral finasteride | 1 mg orally once daily. [22] | Evidence of improvement through 2 years in studied men; select after individualized counseling about systemic 5-alpha-reductase inhibition. [22] |
| Low-level laser therapy | Device-based low-level laser treatment; regimen varies by device. [11][16] | Non-drug alternative or adjunct; meta-analysis supports efficacy in men. [11] |
| Platelet-rich plasma | Autologous platelet-rich plasma; protocols vary. [16] | May be considered as an adjunct, but heterogeneous preparation and treatment protocols limit direct comparison with established pharmacotherapy. [16] |

## Treat female pattern hair loss while accounting for reproductive context and mixed shedding

Confirm miniaturization before attributing diffuse hair loss to female pattern hair loss alone.

Topical minoxidil is the FDA-approved treatment for female androgenetic alopecia, and randomized evidence supports 2% topical minoxidil in women. In a cited clinical review, topical minoxidil arrested hair loss or induced mild-to-moderate regrowth in approximately 60% of women; continued therapy is required because withdrawal causes loss of minoxidil-dependent hair. [11][23][8]

Low-dose oral minoxidil, spironolactone, finasteride, dutasteride, hair transplantation, low-level light therapy, and platelet-rich plasma are described as off-label or adjunctive approaches for female pattern hair loss. Their use should follow confirmation of diagnosis and a patient-specific discussion of reproductive potential, systemic exposure, and the more limited or heterogeneous evidence base compared with topical minoxidil. [16][23]

When diffuse shedding is prominent, do not use androgenetic alopecia treatment response as the diagnostic test. Trichoscopy-assisted pull testing can separate a telogen-root pattern consistent with telogen effluvium from dystrophic hairs suggestive of alopecia areata incognita or anagen roots suggestive of scarring disease; treat the coexisting process rather than attributing all shedding to female pattern hair loss. [14]
- Use frontal-versus-occipital trichoscopy to document miniaturization when female pattern hair loss is suspected. [6]
- Consider a scalp biopsy when examination suggests lichen planopilaris or another scarring alopecia, particularly with anagen hairs on pull testing or loss of follicular openings. [14][24]
- Frame oral minoxidil, antiandrogens, and 5-alpha-reductase inhibitors as off-label in female pattern hair loss. [23]

*Management choices in female pattern hair loss. [11][16][23]*

| Therapy class | Regulatory/evidence position | Selection point |
| --- | --- | --- |
| Topical minoxidil | FDA-approved for female androgenetic alopecia; 2% topical minoxidil is supported by randomized evidence. [11][23] | Preferred pharmacologic foundation when treatment is desired and diagnosis is secure. [11][23] |
| Low-dose oral minoxidil | Off-label. [23] | Consider only after individualized discussion of systemic therapy and monitoring needs. [23] |
| Spironolactone | Off-label antiandrogen approach. [23] | Reserve for individualized use after confirming female pattern hair loss and considering reproductive context. [23] |
| Finasteride or dutasteride | Off-label 5-alpha-reductase inhibitor approaches in women. [23] | Do not extrapolate male trial results directly; use individualized counseling. [22][23] |
| Low-level light therapy or platelet-rich plasma | Adjunctive options with evidence assessed in systematic reviews and network meta-analysis. [11][16] | Discuss protocol variability and comparative uncertainty before committing to repeated procedures or device cost. [16] |

## Measure response, address adherence, and escalate only after reassessing the diagnosis

Objective documentation prevents premature therapy switching and detects a new competing alopecia.

Use baseline and serial standardized scalp photographs together with the same patterned-area clinical and trichoscopic assessment. Trial outcomes in finasteride studies used hair counts, patient and investigator assessments, and expert photographic review; in routine practice, reproducible photography and visible stabilization or regrowth are practical longitudinal measures. [22]

At follow-up, first determine whether treatment was continued, because interruption of topical minoxidil can produce rapid shedding of treatment-dependent hair. If shedding accelerates despite continued therapy, repeat pull testing and trichoscopy rather than automatically intensifying androgenetic alopecia treatment; new dystrophic hairs, anagen roots, or loss of follicular openings shift management toward alopecia areata or scarring alopecia evaluation. [8][14][24]

Consider hair transplantation for advanced stable androgenetic alopecia when medical therapy has been used to preserve remaining native hair and the patient accepts that surgery redistributes follicles rather than halting progression. Hair transplantation is recognized as a surgical option, including in advanced disease, but it does not replace ongoing management of progressive miniaturization. [8][17][23]
- Escalate to scalp biopsy for diagnostic discordance: apparent pattern loss plus inflammatory/scarring trichoscopic findings, anagen hairs on pull testing, or absent follicular openings. [14][24]
- Do not interpret post-discontinuation shedding as definitive disease progression without establishing whether minoxidil was stopped or inconsistently used. [8]
- Use low-level laser therapy, platelet-rich plasma, or transplantation as preference-sensitive adjuncts after communicating variation in protocols and the need for sustained management. [16][23]

*Follow-up findings and actions in treated androgenetic alopecia. [8][14][22][24]*

| Follow-up finding | Likely implication | Action |
| --- | --- | --- |
| Stable or improving serial photographs | Compatible with treatment benefit; finasteride trials used photographic and hair-count outcomes. [22] | Continue the effective regimen and reinforce long-term adherence. [8][22] |
| Rapid shedding after stopping minoxidil | Loss of minoxidil-dependent hairs. [8] | Clarify interruption and discuss resuming continuous topical treatment if appropriate. [8] |
| Dystrophic hairs during diffuse shedding | Raises concern for alopecia areata incognita. [14] | Reassess diagnosis rather than simply adding androgenetic alopecia therapies. [14] |
| Anagen roots or absent follicular openings | Raises concern for a scarring alopecia. [14][24] | Obtain scalp biopsy and direct treatment to the scarring process. [14][24] |

## References
1. Two Phase 3 Trials of Baricitinib for Alopecia Areata — www.nejm.org — https://www.nejm.org/doi/pdf/10.1056/NEJMoa2110343
2. A randomised, double-blinded, placebo-c - The Lancet — www.thelancet.com — https://www.thelancet.com/pdfs/journals/eclinm/PIIS2589-5370(21)00258-3.pdf
3. Safety and efficacy of ALRV5XR in men with androgenetic alopecia — www.thelancet.com — https://www.thelancet.com/journals/eclinm/article/piis2589-5370(21)00404-1/fulltext
4. The new regenerative and innovative strategies in hair loss — www.thelancet.com — https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00275-3/fulltext
5. Androgenetic Alopecia Management Strategies | Dermatology | Clinical Sciences | Health sciences | Topics | Nature Index — www.nature.com — https://www.nature.com/nature-index/topics/l4/androgenetic-alopecia-management-strategies
6. Trichoscopy criteria for diagnosing female androgenic alopecia. | Nature Precedings — www.nature.com — https://www.nature.com/articles/npre.2008.1913.1
7. Androgenetic Alopecia – Medical Management : Clinical Dermatology Review — journals.lww.com — https://journals.lww.com/cddr/fulltext/2022/06020/androgenetic_alopecia___medical_management.4.aspx
8. Androgenetic alopecia in men and women - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0738081X00001280
9. ANDROGENETIC ALOPECIA - CURRENT STATUS : Indian Journal of Dermatology — journals.lww.com — https://journals.lww.com/ijd/fulltext/2005/50040/androgenetic_alopecia___current_status.1.aspx
10. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0190962217303067
11. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0190962217303067
12. Efficacy of Human Foreskin Fibroblast–Conditioned... — journals.lww.com — https://journals.lww.com/00066678-202600000-00069
13. Efficacy and Safety of Mesotherapy With 0.5% Minoxidil ... — journals.lww.com — https://journals.lww.com/00066678-202600000-00055
14. Trichoscopy‐assisted hair pull test: A helpful adjunct to trichoscopy for diagnosing and managing alopecias - Tsiogka - 2021 - Australasian Journal of Dermatology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/ajd.13668
15. Perifollicular fibrosis and inflammation in androgenetic alopecia and ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0365059626001212
16. Efficacy of non‐surgical treatments for androgenetic alopecia: a systematic review and network meta‐analysis - Gupta - 2018 - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.15081
17. Pediatric androgenetic alopecia: an updated review - Gomes - 2023 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/ddg.14940
18. Interventions for female pattern hair loss - van Zuuren, EJ - 2016 | Cochrane Library — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007628.pub4/full
19. Scenario: Management | Management | Male pattern hair loss (male androgenetic alopecia) | CKS | NICE — cks.nice.org.uk — https://cks.nice.org.uk/topics/male-pattern-hair-loss-male-androgenetic-alopecia/management/management
20. Hair Loss | Pediatrics In Review - AAP Publications — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/41/11/570/35358/Hair-Loss
21. Interventions for female pattern hair loss - van Zuuren, EJ — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007628.pub4/references
22. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/9777765
23. Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/41714473?otool=nynyumlib&myncbishare=nynyumlib
24. Diagnostic Yield and Clinical Impact of Trichoscopy in Alopecia: A Cross-Sectional Study From a Rural Tertiary Care Centre - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13504656

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.